(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(S)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-piperidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835322

PubChem CID: 56659923

Max Phase: Preclinical

Molecular Formula: C26H41N5O10

Molecular Weight: 583.64

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CCCC[C@H]1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI:  InChI=1S/C26H41N5O10/c1-12(2)20(27-14(5)32)24(38)28-15(10-18(33)34)22(36)30-21(13(3)4)25(39)31-9-7-6-8-17(31)23(37)29-16-11-19(35)41-26(16)40/h12-13,15-17,20-21,26,40H,6-11H2,1-5H3,(H,27,32)(H,28,38)(H,29,37)(H,30,36)(H,33,34)/t15-,16-,17-,20-,21-,26?/m0/s1

Standard InChI Key:  SJKUPJSYABBYEV-VCEFXLGMSA-N

Molfile:  

     RDKit          2D

 41 42  0  0  0  0  0  0  0  0999 V2000
    3.6438    2.0725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3089    2.5586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0526    3.3426    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.2275    3.3434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9761    2.5576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7398    4.0148    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.0893    2.3080    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.6389    1.2446    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9394    0.8130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2682   -0.4494    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8703   -0.5419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1643   -0.1220    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5897   -0.1381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8611   -1.3657    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4448   -0.5259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7346   -0.1060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4355   -1.3497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1457   -1.7696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7161   -1.7536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0193   -0.5099    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7439    0.7178    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3091   -0.0900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5897   -0.4938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3184    0.7339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5804   -1.3176    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6082    1.1538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1120    0.7489    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6166    1.9766    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1163   -0.0739    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8358   -0.4777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5419   -0.0579    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8451   -1.3016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1349   -1.7215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5604   -1.7054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5447    0.7659    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2928   -1.2727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0163   -1.6618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7195   -1.2296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6947   -0.4039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9665   -0.0105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2127    1.2012    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
 11 12  1  0
 11 13  1  0
 11 14  2  0
 12 15  1  0
 15 16  1  0
 15 17  1  6
 17 18  1  0
 17 19  1  0
 16 20  1  0
 16 21  2  0
 20 22  1  0
 22 23  1  0
 22 24  1  1
 23 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  2  0
 23 29  1  0
 29 30  1  0
 30 31  1  0
 30 32  1  6
 32 33  1  0
 32 34  1  0
 31 10  1  0
 31 35  2  0
 10 36  1  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
 40 10  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 40 39  1  0
 40  9  1  6
  9  8  1  0
  1  5  1  0
  9 41  2  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CASP3 Tchem Caspase-3 (3632 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 583.64Molecular Weight (Monoisotopic): 583.2853AlogP: -1.62#Rotatable Bonds: 12
Polar Surface Area: 220.54Molecular Species: ACIDHBA: 9HBD: 6
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26CX Basic pKa: CX LogP: -1.72CX LogD: -4.71
Aromatic Rings: Heavy Atoms: 41QED Weighted: 0.14Np Likeness Score: 0.14

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C..  (2011)  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.,  19  (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors.  2006-03-09  Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.  [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors.  2011-10-01  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.  [PMID:21903398]

Source